Fosaprepitant
As of the edition of 20 October 2026, Fosaprepitant is a small molecule: marketed, first approved in 2008 (EU); acts on TACR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Emend
- First approved
- 11 January 2008 (EU)
- Approvals on record
- 10 in 5 regions
- Holder of the most recent approval
- Avyxa; 5 holders in all
- Registered trials
- 42, 9 stopped early
- Disease areas
- Cancer; Blood and lymph; Urinary and reproductive; Digestive system; Ear, nose and throat; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Fosaprepitant.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TACR1 | Substance-P receptor | P25103 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 3 | 1 | 0 |
| Phase 1 | 7 | 4 | 0 | 3 |
| Phase 2 | 11 | 5 | 0 | 5 |
| Phase 3 | 13 | 9 | 2 | 1 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 42 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Applicant and Lead sponsor of trials | 2005 to now |
| Ono Pharmaceutical | Applicant | 2011 to now |
| Teva | Applicant | 2019 to now |
| Steriscience | Acquired holder | 2023 to now |
| Avyxa | Later holder | 2026 to now |